Try our Advanced Search for more refined results

FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

  1. August 21, 2017

    Impax Loses Fees Bid In Opioid Pay-For-Delay Row With FTC

    A Pennsylvania federal judge on Monday declined to grant fees to Impax Laboratories Inc. after the Federal Trade Commission voluntarily dismissed its pay-for-delay suit over generic versions of an opioid, but admonished the agency for conduct that had been "less than admirable."

  2. March 14, 2017

    FTC Fights Impax Bid For Fees In Pay-For-Delay Case

    The Federal Trade Commission has argued it cannot be placed on the hook for legal fees and litigation costs after voluntarily dismissing a pay-for-delay suit in Pennsylvania federal court against Impax Laboratories and others over generic versions of an extended-release opioid.

  3. February 21, 2017

    Impax Says FTC Should Pay For Withdrawn Pay-For-Delay Suit

    Impax Laboratories told a Pennsylvania federal court on Friday that the U.S. Federal Trade Commission should be on the hook for litigation costs and attorneys' fees associated with a pay-for-delay suit filed against the company and others that was withdrawn 10 months later and refiled as an administrative action.

  4. November 09, 2016

    Impax Case Dies With Endo Pay-For-Delay Suit, FTC Says

    The Federal Trade Commission's dismissal of a pay-for-delay suit against Endo Pharmaceuticals Inc. over pain drugs Opana ER and Lidoderm should apply to Impax Laboratories Inc. too, which was terminated from the case after it was severed, the FTC told a Pennsylvania federal court Wednesday.

  5. November 08, 2016

    FTC Wins Dismissal Of Opana, Lidoderm Pay-For-Delay Suit

    A Pennsylvania federal judge granted the U.S. Federal Trade Commission's request to dismiss its pay-for-delay suit against Endo Pharmaceuticals Inc. over pain drugs Opana ER and Lidoderm on Tuesday after Endo succeeded in splitting the case in two.

  6. October 31, 2016

    Endo Says FTC Needs Permission To Pull Pay-For-Delay Suit

    Endo Pharmaceuticals Inc. on Monday found itself in the unusual position of arguing to keep open the U.S. Federal Trade Commission's pay-for-delay suit against the company over pain drugs Opana ER and Lidoderm.

  7. October 27, 2016

    Endo Seeks Ruling On FTC Ability To Sue Over Past Conduct

    Endo Pharmaceuticals Inc. has asked a Pennsylvania federal court to rule on whether the U.S. Federal Trade Commission can sue in federal court over conduct that has occurred in the past, an issue in its ongoing antitrust dispute with the agency over the drugs Opana ER and Lidoderm.

  8. October 20, 2016

    Judge Splits FTC's Endo Case, Scoffs At Transfer Threat

    A Pennsylvania federal judge on Thursday split the Federal Trade Commission's suit accusing Endo and other drug companies of illegally delaying Opana ER and Lidoderm generics and challenged the government to follow through with its "cavalier" threat to refile the suits in other districts, saying he'd consider holding it on the hook for fees.

  9. September 06, 2016

    FTC Says Allergan Must Face Lidoderm Generic Delay Suit

    The Federal Trade Commission told a Pennsylvania federal judge on Tuesday that it rightfully sued Allergan PLC alongside Endo Pharmaceuticals and other companies over allegedly unlawful delays in generic drug competition stemming from patent litigation settlements, several days after it pushed back against the companies' bid to dodge the suit altogether.

  10. August 01, 2016

    FTC Urges Quick Ruling On Lidoderm, Opana Severance Bid

    The Federal Trade Commission urged a Pennsylvania federal court Friday to go ahead and decide whether to sever the agency's case claiming an Allergan PLC unit delayed generic competition for Lidoderm from a similar case over Opana ER instead of waiting to rule on a motion to dismiss.